Australia markets close in 4 hours 22 minutes

ImmunoPrecise Antibodies Ltd. (IPA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.12-0.88 (-6.29%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close14.00
Open13.83
Bid9.12 x 900
Ask14.95 x 800
Day's range12.89 - 14.05
52-week range12.73 - 33.34
Volume49,367
Avg. volume128,414
Market cap239.079M
Beta (5Y monthly)0.12
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™ Monoclonal Antibody Cocktail Candidate Against COVID-19
    Business Wire

    ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™ Monoclonal Antibody Cocktail Candidate Against COVID-19

    ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamsters of IPA’s proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease. In a preclinical study using a SARS-CoV-2 hamster model, treatment with IPA’s TATX-03 resulted in complete clearance of detectable replication-competent virus from the lungs and throat of SARS-CoV-2 infected animals.

  • Business Wire

    IPA Announces Closing of Over-Allotment Option Associated with the Recently Completed Bought Deal Offering of Common Shares

    IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that the over-allotment option (the "Option") granted in connection with its previously announced bought deal offering of 1,616,293 common shares (the "Common Shares") in the capital of the Company (the "Offering"), has been fully exercised. H.C. Wainwright & Co. has purchased additional 242,443 shares of the Company (the "Additional Shares") at the public offering price of $13.45 per Additional Share for additional aggregate gross proceeds to the Company of approximately $3.3 million, less underwriting discounts and commissions.

  • IPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares
    Business Wire

    IPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares

    IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that, it has closed its previously announced public offering (the "Offering") of 1,616,293 common shares of the Company (the "Common Shares"), at a price to the public of $13.45 per Common Share, less underwriting discounts and commissions, for gross proceeds to the Company of approximately $21.7 million.